Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, rising over 7% during trading, attributed to a strategic equity transfer agreement with 海松资本 and an industry partner, aimed at optimizing capital allocation and focusing on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock price increased by 6.12%, reaching 7.8 HKD, with a trading volume of 23.94 million HKD [1] Group 2: Strategic Agreement - 加科思 has signed an equity transfer agreement where 海松资本 will pay a total of 2 billion RMB (1.25 billion RMB upfront and 750 million RMB milestone payment) to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products, including KRAS, MYC, P53, and tumor immunology [1] - The proceeds from the equity transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

股票名称 回购数 回购额 年累计回购数量(股) 年累计回购数量/总股本 小米集团-W(01810) 1070.00 万 4.94 亿 2729.54 万 0.110% 四环医药(00460) 1500.00 万 2175.75 万 5959.60 万 0.647% 蒙牛乳业(02319) 120.00 万 1696.90 万 1851.60 万 0.473% 瑞声科技(02018) 30.00 万 1159.88 万 30.00 万 0.026% 速腾聚创 (02498) 29.00 万 991.75 万 29.00 万 0.061% 中通快递-W(02057) 44.50 万 840.97 万 506.72 万 0.630% VITASOY INT'L(00345) 102.00 万 819.55 万 566.60 万 0.540% 云工场(N23027) 202.00 万 814.36 万 2264.30 万 4.922% 联易融科技-W(09959) 252.00 万 744.46 万 6298.90 万 2.948% 碧桂园服务(06098) 100.00 万 618.60 万 1125.50 万 0 ...

Summary of Key Points Core Viewpoint - 加科思-B (01167.HK) announced a share buyback of 135,000 shares at a cost of HKD 990,000 on October 17 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 990,000, reflecting the company's financial strategy [1] - The number of shares repurchased was 135,000, which may influence the stock's liquidity and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

海松资本负责人表示，计划明年上半年提交IND，把管线正式 推入临床阶段。待获取临床安全性与初步疗效数据后，该公司 将择机与跨国药企开展BD合作。 作者： 刘晓诺 封图：图虫创意 加科思的主要业务是肿瘤创新药，而本次交易涉及的是此前未曾披露的心血管治疗项目，该项目原由加科瑞康持有。加科瑞康是加科思控股的北京加科 思的全资子公司。 本次交易的合作方主要是海松资本。交易完成后，海松资本将获得加科瑞康80%的股权，北京加科思与一名未披露的产业合作方各自拥有10%的股 权。海松资本要向北京加科思支付1.25亿元的首付款，以及7500万元的第二期里程碑付款。 据加科思的公告，这2亿元的股权转让对价拟用于其核心肿瘤管线的研发、生产及商业化。 10月16日，加科思相关负责人向经济观察报表示，剥离非核心资产后，公司的战略可以更加聚焦在肿瘤领域，现金流也得到了补充。加科思保留了加 科瑞康10%的股权，可享受未来的更大收益。 出售早期心血管药物管线 在本次交易公告之前，加科思并未公开披露自己在心血管领域的布局。 10月16日上午，加科思董事长兼首席执行官王印祥在电话会上表示，加科思利用临床前研究优势，在小分子、ADC、抗体和其他等 ...

Core Viewpoint - The announcement by Gakos-B (01167.HK) regarding a capital increase and equity transfer transaction highlights a strategic shift towards focusing on its core oncology business while divesting non-core assets, specifically a cardiovascular treatment project [2][3]. Group 1: Transaction Details - Gakos-B has entered into a transaction where Haisheng Capital will acquire 80% of the equity in Gakos-Rikang, a wholly-owned subsidiary of Gakos-B, for a total consideration of 200 million yuan, which will be used to support the development, production, and commercialization of its core oncology pipeline [2][4]. - The payment structure includes an initial payment of 125 million yuan and a milestone payment of 75 million yuan [2]. Group 2: Strategic Focus - Following the divestment, Gakos-B aims to concentrate its resources on the oncology sector, which is deemed more suitable for the company's current development stage [3][4]. - The company retains a 10% stake in Gakos-Rikang, allowing it to benefit from potential future gains [2]. Group 3: Investment and Development Plans - Haisheng Capital, a diversified investment firm with over 25 billion yuan under management, sees significant potential in the Chinese innovative drug sector and plans to leverage clinical advantages in China to expedite the development of the cardiovascular pipeline [4][5]. - Gakos-B's 200 million yuan from the equity transfer is expected to cover a substantial portion of its research and development expenses for the next six months, with a focus on the Pan-KRAS inhibitor and other innovative oncology projects [5][9]. Group 4: Research and Development Focus - The Pan-KRAS inhibitor is a priority for Gakos-B, which aims to develop a leading global product in this area, as KRAS mutations are linked to a significant percentage of cancer cases [6][8]. - Gakos-B is currently conducting I/IIa phase clinical trials for its Pan-KRAS inhibitor in both China and the United States, with results expected in mid-2026 [9].

加科思药业 20251016 摘要 嘉克斯以数亿人民币首付款及 7,500 万人民币里程碑付款，出售非肿瘤 早期项目，保留 10%股权，成功实现资金回笼，展示了其在非肿瘤领域 早期项目布局及收益能力。 嘉克斯在 KRAS 通路药物研发方面处于领先地位，Pancreatic23,173 临床前数据良好，安全性及疗效符合预期，预计年底完成 RPTD 剂量， 明年上半年公布临床一期数据。 海通资本看好嘉克斯心血管项目技术平台的广泛应用潜力，将利用其资 源协同其他投资项目，加速该项目发展，嘉克斯保留 10%股权，有望持 续受益。 嘉克斯开发出 EGFR G12D 抑制剂作为 TADC 载荷，大幅提高疗效并降 低毒性，通过 TADC 技术显著提高药物浓度在肿瘤组织中的积累，扩大 治疗窗，提高安全性。 嘉克斯选择 EGFR 作为 ADC 靶点，基于其在结直肠癌治疗中的重要性， 并计划将 TAD-EGFR KRAS G12D ADC 用于结直肠癌，以提高疗效和 安全性。 Q&A 嘉克斯公司近期与海通资本达成的心血管资产交易的具体情况是什么？这对公 司的资金和未来发展有何影响？ Revolution 公司的分子胶技术虽覆盖范 ...

Core Viewpoint - 加科思-B (01167.HK) experienced a significant increase in stock price, opening nearly 3% higher and currently trading at 8 HKD, reflecting a rise of 2.43% with a trading volume of 470,400 HKD [1] Summary by Category - **Stock Performance** - The stock opened nearly 3% higher and is currently up 2.43% at 8 HKD [1] - The trading volume reached 470,400 HKD [1]

在临床数据不断验证、核心管线逐步进入后期开发的过程中，加科思有望凭借"高管增持+管线价值释 放"的双轮驱动，逐渐获得市场重估。 10月16日，加科思药业(01167)宣布其全资子公司北京加科思新药研发有限公司("北京加科思")与山西海 松管理咨询合伙企业(有限合伙)("海松资本")及一名产业合作方签署增资及股权转让协议。根据协议， 海松资本将以人民币2亿元收购北京加科思旗下北京加科瑞康医药（002589）科技有限公司("加科瑞 康")80%的股权。交易完成后，北京加科思、海松资本及产业合作方将分别持有加科瑞康10%、80%及 10%的股权。 加科瑞康是加科思公司早期心血管研发项目的项目公司，此次交易体现了加科思聚焦肿瘤创新药管线的 长期战略方向，有助于优化资源配置、提升组织效率，并通过风险共担模式保留项目未来价值。 除了KRAS G12C与pan-KRAS，加科思正在推进二代产品EGFR-KRAS G12D tADC。该项目通过EGFR 抗体实现精准递送，同时将KRAS G12D抑制剂作为高效载荷，或成为结直肠癌领域的大单品，公司预 计将在2026年下半年提交IND申请。日后，加科思有望通过不同的弹头与不同的 ...